Advanced Search:
Equity Index

ADOC.PA - ADOCIA

€8.60  -0.01 (-0.12%)

Updated: 08:44 May 10, 2024 EST

Next Session's AI Forecast

96.09%

Avg. Accuracy (AI)

€8.01

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

€8.43

ADOCIA's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ADOCIA - HISTORICAL DATA 6M

  • Last price

    €8.60

  • Daily change

    €-0.01

  • Previous Close

    €8.61

  • Last Updated

    08:44 May 10, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.44 -0.33 -0.22 0.07 0.46

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.3 2.22 2.88 3.32 4.65

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
38.1% 39.06% 58.06% 23.38%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
8.6 1.18% 8.5 -2.63% 8.73 -5.42% 9.23

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.87 -1 1.22 46.52

ADOCIA Technical Analysis News

ADOCIA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Sectors: Healthcare
Industry: Biotechnology
Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Corporate Governance

Adocia SA’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 9; Compensation: 10.